Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cost-Effectiveness Studies Support Medtronic's HeartWare HVAD

Executive Summary

A cost-effectiveness analysis of the LATERAL trial shows patients treated with Medtronic’s HeartWare HVAD through the less-invasive thoracotomy procedure incurred lower hospitalization and medical supply costs than patients implanted with a ventricular assist device through the traditional sternotomy approach. Another new analysis shows HeartWare HVAD is more cost-effective than ventricular assist devices of the past.


Related Content

ENDURANCE Analysis Shows Blood-Pressure Management Reduces Stroke Risk In VAD Patients
Clinical Data Double-Boost Supports Medtronic's HeartWare Investment


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts